Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.82 |
| ▸ | PDE4A | P27815 | 1/20 | 0.82 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.38 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.37 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.37 |
| ▸ | NECTIN4 | Q96NY8 | 3/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.35 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Surotomycin SCHEMBL13246889 | 1.00 | CTSL (0.82) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| Surotomycin SCHEMBL15177344 | 1.00 | CTSL (0.82) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| Surotomycin SCHEMBL17284900 | 1.00 | CTSL (0.82) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| Surotomycin SCHEMBL13246848 | 1.00 | CTSL (0.82) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| Surotomycin SCHEMBL13267854 | 1.00 | CTSL (0.82) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| Surotomycin SCHEMBL29497451 | 1.00 | CTSL (0.82) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL13246857 | 1.00 | CTSL (0.83) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL13246850 | 0.99 | CTSL (0.81) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL25541987 | 0.96 | CTSL (0.75) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL25541971 | 0.96 | CTSL (0.75) | CTSLDRD1PTGS1PDE4AEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| WO-2025059113-A1 | TREATMENTS FOR ENHANCING IMMUNE RESPONSE TO CLOSTRIDIOIDES DIFFICILE INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026090542-A1 | BETA-AMINO-ESTER AND BETA-THIOL-ESTER CONTAINING POLYMERS FOR DRUG DELIVERY AND PHARMACEUTICAL USES | EMORY UNIVERSITY (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12601740-B2 | Method and kit for identifying antimicrobial agents and effective concentrations thereof | COBIO DIAGNOSTICS INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260085341-A1 | Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens | UNIV EMORY (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2022112595-A1 | NOVEL REPLICATION DEFICIENT INFLUENZA A VIRUS INDUCING HIGH LEVELS OF TYPE I INTERFERON | BLUESKY IMMUNOTHERAPIES GMBH (AT) | 2022-06-02 | — | — | WO | disclosed |
| US-20220143040-A1 | ANTIVIRAL TREATMENT | CEBINA GmbH (AT) | 2022-05-12 | — | — | US | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11273163-B2 | Antiviral treatment | CEBINA GmbH (AT) | 2022-03-15 | — | — | US | disclosed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | disclosed |
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-11246312-B2 | Antimicrobial compositions and methods of using same | CROWPIERCE TECHNOLOGIES, LLC (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | CTSL 56/4885DRD1 4874/4885PTGS1 1118/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | CTSL 1003/4885DRD1 302/4885PTGS1 3055/4885 |
| US-20260085341-A1 | Using Multiple Heteroresistance to Guide Combination Antimicrobial Regimens | Q6ZSR9, AMPD2, AMPD1 | CTSL 126/4885DRD1 936/4885PTGS1 4860/4885 |
| US-12601740-B2 | Method and kit for identifying antimicrobial agents and effective concentrations thereof | MYD88, TNFSF11, TNF | CTSL 141/4885DRD1 2403/4885PTGS1 4363/4885 |
| US-20220143040-A1 | ANTIVIRAL TREATMENT | ACE, SARS1, TRIM25 | CTSL 83/4885DRD1 747/4885PTGS1 2167/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | CTSL 1755/4885DRD1 4725/4885PTGS1 1138/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | CTSL 562/4885DRD1 3675/4885PTGS1 3510/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | CTSL 790/4885DRD1 3490/4885PTGS1 3935/4885 |
| US-11273163-B2 | Antiviral treatment | ACE, SARS1, TRIM25 | CTSL 90/4885DRD1 635/4885PTGS1 2614/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | CTSL 886/4885DRD1 2192/4885PTGS1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.